GRAY, DAVID LAWRENCE FIRMAN,ZHANG, LEI,DAVOREN, JENNIFER ELIZABETH,DOUNAY, AMY BETH,EFREMOV, IVAN VIKTOROVICH,MENTE, SCOT RICHARD,SUBRAMANYAM, CHAKRAPANI
申请号：
CA2946471
公开号：
CA2946471C
申请日:
2015.04.09
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof； processes for the preparation of； intermediates used in the preparation of； and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
